The Brazilian Health Regulatory Agency (ANVISA) granted approval for the FlareHawk7 and FlareHawk9 spine implant devices.

“We are excited about our recent ANVISA approval to market both our FlareHawk7 and FlareHawk9 implants in Brazil, marking another step toward delivering cutting-edge spinal solutions worldwide,” President and CEO Kevin McGann said in a news release. “This approval highlights our commitment to meeting the needs of spine surgeons globally and ensuring more patients can benefit from our innovative solutions designed to elevate the surgeon experience and outcomes.”